Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial
Results Conference Call and Webcast
SAN DIEGO, March 7, 2013
SAN DIEGO, March 7, 2013 /PRNewswire/ --Orexigen® Therapeutics, Inc. (Nasdaq:
OREX), a biopharmaceutical company focused on the treatment of obesity, will
announce financial results for the full year and fourth quarter ended December
31, 2012, on Wednesday, March 13, 2013 after the markets close. The
announcement will be followed by a live webcast and conference call at 5:00
p.m. Eastern time (2:00 p.m. Pacific time).
Orexigen management will host the call and webcast to discuss financial
results and recent business highlights. The live call may be accessed by phone
by calling (888) 895-5479 (domestic) or (847) 619-6250 (international),
participant code 34404715. The webcast can be accessed live on the investor
relations section of the Orexigen web site at www.orexigen.com and will be
archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave^®,
which has completed Phase III clinical trials and for which a New Drug
Application has been submitted and reviewed by the FDA. The Company has also
reached agreement with the FDA on a Special Protocol Assessment (SPA) for the
Light Study, the Contrave cardiovascular outcomes trial. The Company's other
product candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.
Vice President, Corporate Communications & Business Development
SOURCE Orexigen Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.